Chronic Total Occlusions: The Road Less TraveledAllina Health
By M. Nicholas Burke, MD. The use of pioneering percutaneous treatments for chronic total occlusions: indications, limitations, outcomes and current research.
Chronic Total Occlusions: The Road Less TraveledAllina Health
By M. Nicholas Burke, MD. The use of pioneering percutaneous treatments for chronic total occlusions: indications, limitations, outcomes and current research.
Safety and efficacy of using a single transradial MAC guiding catheter for coronary angiography and intervention in patients with ST-elevation myocardial infarction (RAPID)
Safety and efficacy of using a single transradial MAC guiding catheter for coronary angiography and intervention in patients with ST-elevation myocardial infarction (RAPID)
Optimize guide catheter support
Fabrice Leroy, Lille, France
11th Experts Live CTO
The annual Euro CTO meeting
September 13th –14th, 2019 - Berlin, Germany
Antegrade approach to coronary chronic total occlusionRamachandra Barik
We provide our initial experience with the Fielder XT-R
and XT-A wires in a contemporary population of unselected CTO patients treated at a single center. We believe our
results show excellent performance for the XTRA wires in
both procedural success and wiring times, with relative improvements as compared with historical reports throughout
the spectrum of lesion complexity. We suggest operators consider starting with these wires as part of an initial antegrade
wiring approach and speculate that technological advancements such as the XTRA wires may change the spectrum of
lesion recommended for an antegrade-first approach
15th Experts Live CTO - Carlo Di Mario: ConclusionsEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Francesco Burzotta: Wrap up Gemelli CasesEuro CTO Club
PLENARY SESSION
Wrap up of live cases, awards to the winners of the best abstracts and case competitions and take home messages
Auditorium Zubin Mehta - Saturday 16:00 - 17:00
Speakers:
Daniela Benedetto (Rome),
Francesco Burzotta (Rome),
Carlo Di Mario (Florence),
Roberto Garbo (Turin),
Rocco Stio (Rome)
Challengers:
Stelios Pyxaras (Furth - D),
Sudhir Rathore (London - UK)
Discussants:
Shunsuke Matsuno (Tokyo - J),
Alexander Nap (Amsterdam - NL),
Masahisa Yamane (Tokyo - J)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Jonathan Hill: Role of mechanica support in CTO recanalizationEuro CTO Club
10:42
Role of mechanica support in CTO recanalization
Jonathan Hill (London - UK)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Gregor Leibundgut: Role of DEB in CTO-PCIEuro CTO Club
10:35 Role of DEB in CTO-PCI
Gregor Leibundgut (Basel - CH)
___________________________________________
PARALLEL SESSION
Challenges And Opportunities In Cto Recanalization
Auditorium Zubin Mehta - Saturday 10:00 - 11:10
Chairperson:
Jonathan Hill (London - UK)
Discussants:
Lesnek Bryniarski (Krakow - PL),
Ugo Fabrizio (Vercelli),
Paul Knaapen (Amsterdam - NL),
Eugenio La Scala (Ollioiouls - F)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Kambis Mashayekhi: EuroCTO Consensus on treatment of Calcified CTO lesion Eur...Euro CTO Club
AUDITORIUM ZUBIN MEHTA
08/09/2023 04:30 - 05:20
PLENARY SESSION - INTERVENTIONAL CTO & CHIP RESEARCH Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Euro CTO Club
16:53
CTO PCI Outcome associated with poor quality of the distal target vessel
Emmanouil Brilakis (Minneapolis - USA)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Mario Iannaccone - 2 EuroCTO Consensus on Guide Catheter Extensions JACC Card...Euro CTO Club
16:33
EuroCTO Consensus on Guide Catheter Extensions JACC Cardiovasc Interventions
Mario Iannaccone (Turin)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Pharma Pcd Franchise in Jharkhand - Yodley Lifesciences
CTO in India
1. IJCTO & IMPACT ON CTO–
PCI IN INDIA
Dr V Suryaprakasa Rao
Head of Cardiology Apollo Hospitals
Hyderguda Hyderabad - India
Course director – IJCTO
2.
3. • To benefit large pool of CTO patients in
India.
• To improve outcomes – short and long
term with use of improvised skills from
world and access to better devices and
stents
• To train fellows across India and Indian
Sub continent.
• To provide cost effective CTO – PCI to
low affordable groups in India.
Objectives:
4. INDIAN FOUNDER MEMBERS :
• Dr V. Surya Prakasa Rao
Apollo Hospitals, Hyderguda, Hyderabad, India.
• Dr A.V.Ganesh Kumar
L.H.Hiranandani Hospital, Mumbai, India.
• Dr P.K.Goel
SGPGI, India
• Dr Pratap Kumar.N.
Meditrina Group of Hospitals, India.
ASSOCIATE MEMBERS :
DRPLNKAPARDHI DRANILDHAL DRRAMANCHAWLA
DRTRAJESH DRDDASH DRP.KANTILALSHAH
5. HONORARY JAPANESE
MEMBERS:
DR E.TSUCHIKANE
Dr M OCHAI
DR KENYA NASU
DR MURAMATSU
DR ASAKURA
DR YAMANANE
DR Y HAMAZAKI.
VISTING EUROPEAN
FACULTY :
DR A GALASSI
DR G SIANOS
DR G WERNER
6. Situation in year
1994 - CTO PCI
Simple mid RCA CTO
Reasons being no
dedicated hardware
and skills of
interventionists
1994
7. PCI Trends in India last 20 years
No of Cath labs in
1994 = 40
PCI including POBA and
beginning of BMS
procedure time 2 hrs.
PCI total procedures
25000
No complex cases
CTO not known
No of Cath labs in
2017 = app 1000
PCI load = 3,50,000
procedures
CTO accounts to approx.
6% of PCI.
IJCTO group contributed
for this development
Retrograde trend is
growing
19. Attempted
Case of HTN / ACS / 2VD / Normal LV function / Attempted PCI to RCA (11/2016)
20. Attempt 2nd time (01/2017), Rt FA approach, Antegrade approach, 7F, Al1,
RCA proximal segment with multiple dissecting planes,
Wires: Fielder XT R, GAIA series, Conquest Pro, Miracle -3, Pilot series finally
ULTIMATE BROS 3 with Corsair 135 support.
Procedure Abandoned for Air Kerma > 5 Gray
Fluoro Time : 104 Mins
Contrast : 360 ml
J CTO Score: 3
ULTIMATE BROS -3
21. Attempt 3rd time (04/2017),
J CTO Score: 3
Bi femoral approach, 7F, Al1, and EBU 3.5,
RCA proximal segment multiple dissecting planes, retrogradely filling from LCS.
Retrograde approach: Corsair 150 – collateral channels – septals profiled,
Multiple CTO wires escalated finally SUOH 03 crossed via septal connection.
Antegrade approach: Corsair 135 – with Ultimate Bros 03 in sub intimal space,
22. • Reverse cart at CTO Site with 2 & 2.5 NC balloon.
• Wire position checked with rotational Angio and IVUS
• Recapture of wire into guidezilla and externalization
24. N = 1683
Age Range : 29-78
Males : 86.47%
Females : 13.53%
IJCTO DATA
1683 CTO's – Jul 2012-June 2017
25. DISTRIBUTION
26% of Routine CAGs are CTOs
69%
20% 6%
2%
3% Old MI with Class II Anginal
Symptoms
Class II angina/Unstable Angina
Asymptomatic with Provokable
Ischemia
ACS/Ac on Ch
Acute MI with Non Culprit
Vessel CTO
26. Assessment of viability /
inducible ischemia prior to CTO
PCI:
Tread Mill Test : 3.2%
Stress Echo: 2%
Sestamibi Perfussion scan : 1.7%
CMR : 2%
27. in selective cases:
64 - MSCT: 10.7%
to study the length, tortuosity, calcium, caliber of vessel
and collaterals.
A gap of 3 weeks is given between MSCT and PCI.
35. Balloons
1 mm Saphire / 1.1 mm Acrostak/ 1.25 mm Rejuvin
plus, and Mini Trek / 1.5 and 2.00 mm Rejuvin plus,
Tazuna and Maverik,
NC High Pressure dilatation : 2.5 mm , 3.0, 3.5, 4.0 mm
: Hiruyu, Spinter, Trek and Saphire.
38. Stents:
All pts received DES : 2819 stents deployed
18-28 mm :1190/28-38 mm:1210/38-48 mm: 419.
Overlapping stenting done in 410 cases.
Deployed at Nominal atm:10 and High Pressure
dilatation 18 to 24 atm
EES – 68%
PES – 14%
SES- 8%
BVS- 0.6%
ZES: 9.4%
39. PROCEDURE CHARACTERISTICS
• Fluro Time - varies : 54 - 128 Min
• Volume of Contrast varies : 170 -380 ML
• Procedure Time varies : 85 -262 Min
• Success Rate : 89.9%
40. Complications
2.9%
11 septal hematoma
4 case of them had hemodynamic compromise – RV outflow
obstruction.
7 cases of donor artery thrombosis – managed with stenting and
thrombosuction.
5 case of LM ( donor artery ) dissection – needed bailout stenting.
3 case of Intra cavity – type IV perforation – managed
conservatively.
3 case coronary perforation – needing covered stent.
4 case of cardiac tamponade – pericardiocentesis done.
2 case having diagonal closure needed IABP support.
No case required emergency CABGs / no in hospital mortality /
Contrast nephropathy – not leading to dialysis – 9 cases.
41. IVUS : 42% OF CASES (Volcano eagle
eye gold and eagle eye platinum 5F)
FOR THE PROXIMAL CAP PUNTURE
BALLOON SIZING IN REVERSE CART
VESSEL DIAMETER
STENT APPOSITION
DISSECTION
42. Follow up: 3 days /30 days/ 90 days /180 days/ 1 year / >
5 years.
Clinical questionnaire - all cases on follow up
ECG on all cases of follow up
2 D Echo – all cases on follow up
Tread Mill Test – 6months and yearly
MSCT – in selected cases.
Perfusion scan in selected cases
Coronary Angiography – in symptomatic and inducible ischemia pts:
12.8%
Lost follow up: 136pts
43. Follow Up
Quality of life : Improved in 84% ( by clinical questionnaire)
Angina Relief : More than 90%
SAT: 0
Improvement of LV function(11%) Seen more in LAD CTO
ISR : 12%
DEB 1.36% (Paclitaxal / Sirolimus)
TVR Redo PCI 59.7% / CABGs 27.8%
MI – enzymatic MI - rise noted in 14%( two fold increase in
CPK MB ) in hospital.
SCD :5 On Follow up
Death – 21 ( non cardiac )
44. Medication:
DAPT: (>>>Clopidogrel />> Prasugrel / >Ticagrelor) +
Entric coated Aspirin : 1 year
Subsequently – Enteric coated Aspirin
Through out Statins: Atorvastatin 40mg and Rosuvastatin
40mg (monitored liver function and muscle enzymes)
45. Future:
To Structure Current CTO registry in the Indian continent and
expand network by increasing permanent members of IJCTO.
R&D for cost effective CTO devices so More Patients can avail
the CTO PCI.
Slender systems to decrease vascular problems.
To Bring down Radiation hazards for Physician and Patients
Collaboration of IJCTO with major CTO bodies around Globe.
47. 6th Live summit of
IJCTO 2018
Dates: 1st, 2nd & 3rd
June 2018
Venue: Hyderabad,
India
Save your
dates
48.
49. CACTO 2006 facts
• 1st live workshop @ Hyderabad
dedicated to complex cases
• More than 400 delegates
attended two day program
• 6 live transmission cases
• Didactive Lectures of CTO PCI
approach
• Course Directors of CACTO
Dr Suryaprakasa Rao
Dr PLN Kapardhi
CACTO (Complex Angioplasty and Chronic Total Occlusion) a charitable trust is started by
like minded Cardiologists from Hyderabad with a thought and vision for Discussing,
Exchanging and Sharing the experiences and also to Improve the skills in Interventional field
and manyCACTO started its program in the year of 2006
and the Live workshops were coordinated by Dr.S.Saito Dr.M.Ochia, Dr.E.Kyo, Dr.
M.Yammane, Dr.Kenya Nasu all from Japan
50. SAACI 2009 - Trivandrum
SACCI - First Dedicated complex coronary intervention meeting in Kerala started in Apr 2009 with 23
international faculty like Dr Asakura(Japan), Dr Y Louvard(France) Dr Imad Sheban(Italy),
Dr J Scanned (spain) Dr T Ischinger(germany)....etc along with Many Indian Faculty. Live case transmissions
and Focused Lectures.
51. CACTO 2009 facts
• 2ndt live workshop @
Hyderabad dedicated
to complex cases
• More than 400
delegates attended
two day program
• 8 live transmission
cases
• Focused talk on
Retrograde techniques
Image guided PCI
• Course Directors of
CACTO
Dr Suryaprakasa
Rao
Dr PLN Kapardhi
52. CACTO 2012 facts
• 3rd live workshop @ Taj Vivanta,
Hyderabad
• More than 500 delegates attended two
day program
• 12 live transmission cases
• Lectures of CTO PCI approach
• Both Trans Radial and femoral PCI cases
of CTO done.
• Course Directors of CACTO
Dr Suryaprakasa Rao
Dr PLN Kapardhi
Dr. M.Yamane
Dr.E.Tuschikane
Dr.A.Gallasi.
Dr.Kenya Nasu.
Live cases Tx from
Toyohashi Heart Centre, Japan and
C3,Orlando, USA
53. 1st live summit of IJCTO Mumbai, 2013
• 1st Live Congress @ Renaissance Mumbai Convention
Centre Hotel
• More than 600 delegates attended two day program
• 14 live transmission cases
• Peripheral CTO and BVS in CTO demonstrated.
• Sting Ray and Crossboss Live from USA.
• Didactive Lectures of CTO PCI approach
• Course Directors
• Dr M.Yamane
• Dr Muramatsu
• Dr E.Tsuchikane
• Dr. Y.Asakura.
• Dr Kenya Nasu
• Dr Y.Oikawa
• Dr Suryaprakasa Rao
• Dr Prahtap Kumar
• Dr Ganesh Kumar
• Dr PLN Kapardhi
• Dr Abhaichand Rajpal
• Dr.Raman Chawala
• Dr.Anil Dhal.
54. 2nd live summit of IJCTO
Hyderabad,2014.
• 2nd live workshop @ Novotel, HICC, Hyderabad
• More than 620 delegates attended three day program
• 14 live transmission cases
• Fellows Course, Simulators from Ashahi- Etos , Teurmo - TRI and
Crossroads village from Abbott, Peripheral CTO sessions, CD presentations
• Lectures of CTO PCI approach
• Course Directors:
• Dr M.Yamane
• Dr Muramatsu
• Dr E.Tsuchikane
• Dr. Y.Asakura.
• Dr Kenya Nasu
• Dr Y.Oikawa
• Dr. George Sainos
• Dr. Imad Sheiban
• Dr. Van Der Schaff
• Dr. Ashish Pershad
• Dr Suryaprakasa Rao
• Dr Prahtap Kumar
• Dr Ganesh Kumar
• Dr PLN Kapardhi
• Dr Abhaichand Rajpal
• Dr.Raman Chawala
• Dr.Anil Dhal.
• Dr P.K.Ashokan
55. 3rd live summit of IJCTO
Lucknow,2015
• 3rd live workshop @ Lucknow
• More than 680 delegates attended two day
program
• 14 live transmission cases
• Fellows Course, Simulators from Ashahi-
Etos , Teurmo - TRI and Crossroads village
from Abbott, Peripheral CTO sessions, CD
presentations
• Lectures of CTO PCI approach
• Course Directors:
• Dr M.Yamane
• Dr Muramatsu
• Dr E.Tsuchikane
• Dr. Y.Asakura.
• Dr Kenya Nasu
• Dr Y.Oikawa
• Dr. George Sainos
• Dr. G. Werner.
• Dr. E. Lombardi
• Dr Suryaprakasa Rao
• Dr Prahtap Kumar
• Dr Ganesh Kumar